Novartis Targets Breast Cancer Drug Approval to Take on Pfizer : bloomberg

according to bloomberg

Novartis Targets Breast Cancer Drug Approval to Take on Pfizer

Novartis Targets Breast Cancer Drug Approval to Take on Pfizer

An experimental Novartis AG treatment for a form of advanced breast cancer slashed the risks of death and the disease progressing in a study, paving the way for the Swiss drugmaker to seek regulatory approval in the U.S. and Europe by the end of the year.Novartis expects to win the first approval for the drug, ribociclib, by the end of June next year, Alessandro Riva, global head of oncology development and medical affairs at the Basel, Switzerland-based company, said in an interview.Ribociclib, in combination with the older breast-cancer medicine letrozole, cut the risk of worsening or death by 44 percent over letrozole alone in a study of more than 600 people, Novartis said on Saturday.More than half of women taking both medicines saw their tumor size shrink by at least 30 percent.


not to mention pennlive

Here's how central Pennsylvania is marking Breast Cancer Awareness Month

Here's how central Pennsylvania is marking Breast Cancer Awareness Month

Breast Cancer Awareness Month is marked each October worldwide as an effort organized by major breast cancer charities to raise awareness about the disease, provide support for those with breast cancer and to raise funds for research.Here's how central Pennsylvania organizations are supporting the cause.SUNDAYFastpitch for a Purpose: 8 a.m.- 6 p.m. at Crist Field Complex, 495 Emig Road, York.This softball tournament concludes today.